TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02722902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carnitor
Description: CARNITOR® (levocarnitine) is a carrier molecule in the transport of long-chain fatty acids L-Carnitine will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The administration will start with a bolus of 15mg/kg for 10 minutes. Subsequently, continuous L-carnitine infusion of 10mg/kg will start for the remaining 350 minutes.~across the inner mitochondrial membrane.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IntraLipid
Description: Lipid emulsion for infusion

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: IntraLipid
Description: Lipid emulsion for infusion

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline will be used as placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline will be used as placebo
Study: NCT00977600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPN-100
Description: HPN-100 is a triglyceride that has a similar mechanism of action as Buphenyl. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbutyric acid (PBA). PBA is converted to phenyl acetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA that 40 tablets of NaPBA do.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPN-100
Description: HPN-100 is a triglyceride that has a similar mechanism of action as Buphenyl. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbutyric acid (PBA). PBA is converted to phenyl acetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (\~17.4mL) delivers equivalent amount of PBA that 40 tablets of NaPBA do.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ammonul

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buphenyl
Study: NCT01699321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Your Move (physical activity)
Description: Materials that are provided will aim to increase a participant's minutes of physical activity.

Intervention type: OTHER
Group type: OTHER
Intervention: Your Money (financial empowerment)
Description: Materials that are provided to participants will direct them to resources for financial health.
Study: NCT03433443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case manager assisted rehabilitation
Description: In addition to receiving usual physical rehabilitation the patients in the intervention group had a case manager assigned. A team of three case managers delivered the intervention: a medical doctor specialized in social medicine, an occupational therapist, and a social worker. The case managers were all experienced case managers for non-surgical low back pain patients. The allocation to the case manager was random, and all patients had a main case manager assigned. The case managers involved the other case managers if their special knowledge were needed. Barriers for the patient's rehabilitation were discussed with the multidisciplinary team also including a surgeon, a physiotherapist, and a nurse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual physical rehabilitation
Description: The patients received usual physical rehabilitation at their community rehabilitation unit, and had no case manager assigned.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual physical rehabilitation
Description: The patients received usual physical rehabilitation at their community rehabilitation unit, and had no case manager assigned.
Study: NCT01510704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD421
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD421
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD421
Description: IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV
Study: NCT00423137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2948 BS
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2948 BS
Description: Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study: NCT00874718

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: educational program
Description: 6-week educational program for prevention of occupational musculoskeletal diseases.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: General education
Description: Non-specific educational program for general health.
Study: NCT04556149

Intervention type: DEVICE
Intervention: imPulse™ Una e-stethoscope
Description: The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.

Intervention type: DEVICE
Intervention: imPulse™ Una e-stethoscope
Description: The imPulse™ System is an every/anywhere-point-of-care cardiopulmonary functional state assessment platform designed to capture normal and abnormal, audible and inaudible cardiopulmonary sounds, rhythms and patterns, via a real-time, intelligent, full-spectrum phonocardiogram obtained from direct to skin coupling or through a layer of clothing.

Intervention type: DEVICE
Intervention: Philips Lumify Ultrasound System
Description: Point-of-care ultrasound

Intervention type: DEVICE
Intervention: Philips Lumify Ultrasound System
Description: Point-of-care ultrasound
Study: NCT03524170

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT01442597

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment As Usual (TAU)
Description: Treatment normally offered at this clinic which could include individual or group drug counseling sessions one time per week last one hour each time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual clinician-provided CBT
Description: Individual drug counseling sessions with trained clinicians using CBT one time per week last one hour per session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT4CBT
Description: Subjects work with a computerized program that teaches skills for stopping drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session.
Study: NCT00209040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acoustic Startle Testing
Description: See protocol description for methodological details
Study: NCT00431106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine at the dose of 1000 mg/m2 intravenously (IV) every 2 weeks for 12 consecutive cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine at the dose of 1250 mg/m2 twice daily orally (os), from day 1 to day 14, every 3 weeks for 6 consecutive cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Vinorelbine at the dose of 25 mg/m2 IV on day 1 every 2 weeks for 12 consecutive cycles
Study: NCT06727357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: in according to institutional guidelines
Study: NCT04782882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation+laughter therapy
Description: Laughter therapy:Laughter therapy is a technique that changes the mood by breathing correctly and by combining childish exercises with laughter exercises to turn into real laughter for no reason.~Progressive muscle relaxation procedure:~the participants were asked to tighten and relax large muscle groups in the body with deep breathing exercises. Progressive muscle relaxation was applied to the muscles of the head and face, neck, chest, back, arms, hands, abdomen, hips, legs and feet. The procedure was applied in a dark environment and accompanied by candlelight and relaxing music.
Study: NCT03907059

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: whey protein
Description: supplementation individually adjusted to 1.6g/kg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: soy protein
Description: supplementation individually adjusted to 1.6g/kg/day
Study: NCT01779466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (not active)
Study: NCT00197704

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multivitamins
Description: 5000 IU of retinol, 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 of C, 200 mg of E, 0.8 mg of folic acid, and 100 mcg of selenium taken orally on a daily basis from the start of TB therapy through 8 months of anti-TB therapy

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill taken orally on a daily basis from the start of TB therapy through 8 months of anti-TB therapy
Study: NCT02531074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food Journal

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Study: NCT02079376

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DIAMOND System
Description: DIAMOND Implantable Pulse Generator (IPG)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIAMOND System
Description: DIAMOND Implantable Pulse Generator (IPG)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIAMOND System
Description: DIAMOND Implantable Pulse Generator (IPG)
Study: NCT03922191

Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Data extraction from medical files

Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Data extraction from medical files
Study: NCT02977052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery will be done at 6 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery will be done at 6 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery will be done at 6 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery will be done at 6 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood for PBMCs
Description: Blood will be taken for translational research on PBMCs
Study: NCT03266068

Intervention type: PROCEDURE
Intervention: Flexible sigmoidoscopy with colonic biopsies
Description: Endoscopy of the subject's lower colon in which biopsies of the lining of the colon will be taken.

Intervention type: PROCEDURE
Intervention: Small bowel and colonic gastrointestinal permeability
Description: A validated scintigraphic method to measure gastric, small bowel and colonic transit will be used.

Intervention type: PROCEDURE
Intervention: Small bowel and colonic gastrointestinal permeability
Description: A validated scintigraphic method to measure gastric, small bowel and colonic transit will be used.

Intervention type: PROCEDURE
Intervention: Small bowel and colonic gastrointestinal permeability
Description: A validated scintigraphic method to measure gastric, small bowel and colonic transit will be used.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool sample analysis
Description: Stool samples will be used to extract supernatants. These supernatants will be studied in using chamber set-up to determine barrier effects on T84 monolayers.
Study: NCT02977052

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood for PBMCs
Description: Blood will be taken for translational research on PBMCs

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood for PBMCs
Description: Blood will be taken for translational research on PBMCs

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood for PBMCs
Description: Blood will be taken for translational research on PBMCs

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies
Description: Biopsies will be taken during screening and at relapse.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies
Description: Biopsies will be taken during screening and at relapse.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies
Description: Biopsies will be taken during screening and at relapse.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies
Description: Biopsies will be taken during screening and at relapse.
Study: NCT03589066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03003
Description: 28 mg intramuscular suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03003
Description: 28 mg intramuscular suspension
Study: NCT01367366

Intervention type: PROCEDURE
Intervention: PET and EBUS-TBNA
Description: PET and EBUS-TBNA once, respectively
Study: NCT02626962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Ipilimumab every 3 weeks for a total of four doses (Cycles 1 and 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab every 3 weeks for a total of four doses (Cycles 1 and 2) followed by Nivolumab every 2 weeks
Study: NCT02642640

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: melatonin
Description: 5 mg of melatonin per os.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: melatonin
Description: 5 mg of melatonin per os.
Study: NCT01014104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Administration of Methylprednisolone

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Normal salin injection
Study: NCT00187005

Intervention type: DRUG
Group type: OTHER
Intervention: Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase
Description: See Detailed Description section for details of treatment interventions.

Intervention type: DRUG
Group type: OTHER
Intervention: L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine
Description: See Detailed Description section for details of treatment interventions.
Study: NCT04478591

Intervention type: OTHER
Intervention: Questionnaires
Description: All participants will fill in two questionnaires before or during their next treatment with ocrelizumab: the MSIS-29 questionnaire and a wearing-off questionnaire. After two weeks, participants fill in two digital questionnaires (MSIS-29, additional wearing-off questionnaire).
Study: NCT01250691

Intervention type: OTHER
Intervention: ward-type ICU
Description: frequency of hospital acquired pneumonia in the ICU
Study: NCT04487626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI
Description: After taking standard bowel preparation regimen, patients receive colonoscopy under the AI system device. During the withdrawal phase, bowel preparation quality is assessed by AI-associated scoring system. The withdrawal time is targeted at least 6min. Every detected polyp will be removed and obtained for pathological assessment.
Study: NCT03899038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia
Description: Patients will receive real-time ultrasound guided spinal anesthesia using Taylor's approach. Various doses of bupivacaine 0.5% (Bupivacaine hydrochloride injection, Harvest Pharmaceutical CO., LTD., Shanghai, China) will be administered.
Study: NCT02642640

Intervention type: DRUG
Group type: OTHER
Intervention: placebo

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Study: NCT03899038

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal anesthesia
Description: Patients will receive real-time ultrasound guided spinal anesthesia using Taylor's approach. Various doses of bupivacaine 0.5% (Bupivacaine hydrochloride injection, Harvest Pharmaceutical CO., LTD., Shanghai, China) will be administered.
Study: NCT01400659

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CFP counting
Description: Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CFP counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CARB counting
Description: Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CARB counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.
Study: NCT00892710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 IV given over 10 minutes every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 IV given over 10 minutes every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 IV given over 10 minutes every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg IV every 21 days
Study: NCT02462447

Intervention type: DRUG
Intervention: 11C-sarcosine
Description: Radiotracer injection for PET/CT scan

Intervention type: DRUG
Intervention: 11C-sarcosine
Description: Radiotracer injection for PET/CT scan
Study: NCT03266068

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool sample analysis
Description: Stool samples will be used to extract supernatants. These supernatants will be studied in using chamber set-up to determine barrier effects on T84 monolayers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool sample analysis
Description: Stool samples will be used to extract supernatants. These supernatants will be studied in using chamber set-up to determine barrier effects on T84 monolayers.
Study: NCT02342704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fingolimod
Description: Administered as specified in the treatment arm
Study: NCT00726570

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sequential compression device therapy
Description: Pneumatic stockings will be applied to patients.~Pressures ranging from 12 to 40 mmHg will be applied at different levels of the lower limb for 40-second cycles at 2-minute intervals. Therapy will continue until the morning after surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin
Description: * 2500 UI qd if ≤ 50 kg body weight~* 5000 UI qd if \> 50 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin
Description: * 2500 UI qd if ≤ 50 kg body weight~* 5000 UI qd if \> 50 kg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEG
Description: A 2-ml blood sample will be used for each exam. A full analysis will be run both with and without heparinase at each time point.~TEG analyses will be run at:~* Patient admission (before SCD start)~* 40-60 min after admission~* Morning after surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TEG
Description: A 2-ml blood sample will be used for each exam. A full analysis will be run both with and without heparinase at each time point.~TEG analyses will be run at:~* Patient admission (before SCD start)~* 40-60 min after admission~* Morning after surgery
Study: NCT00002882

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin (IL-2)
Description: Infusion for a total of 96 hours on days 1-4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa (IFN-A)
Description: IFN-A Therapy Groups:~Schedule A: IV IFN-A induction 5 times a week for 4 weeks followed by subcutaneous IFN-A maintenance 3 times a week for 48 weeks.~Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks~Adjuvant Biochemotherapy Group: IFN-A is given subcutaneously on days 1-5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa (IFN-A)
Description: IFN-A Therapy Groups:~Schedule A: IV IFN-A induction 5 times a week for 4 weeks followed by subcutaneous IFN-A maintenance 3 times a week for 48 weeks.~Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks~Adjuvant Biochemotherapy Group: IFN-A is given subcutaneously on days 1-5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa (IFN-A)
Description: IFN-A Therapy Groups:~Schedule A: IV IFN-A induction 5 times a week for 4 weeks followed by subcutaneous IFN-A maintenance 3 times a week for 48 weeks.~Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks~Adjuvant Biochemotherapy Group: IFN-A is given subcutaneously on days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV Days 1-4
Study: NCT02462447

Intervention type: DRUG
Intervention: 11C-choline
Description: Radiotracer injection for PET/CT scan
Study: NCT02617186

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Video-assisted thoracoscopic surgery
Description: patients randomized to this arm will receive video-assisted thoracic surgery (VATS)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic thoracic surgery
Description: patients randomized to this arm will receive robotic thoracic surgery (RTS) with the da Vinci Robot
Study: NCT00002882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: IVPB on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: IVPB on days 1-4

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adjuvant Therapy
Description: Patients receiving adjuvant radiotherapy will start adjuvant systemic therapy within 8 weeks from lymphadenectomy and a week after completion of and recovery from radiotherapy.